BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2807180)

  • 1. Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia.
    Malik ST; Tucker J; Rohatiner AZ; Brace W; Lister TA
    Hematol Oncol; 1989; 7(6):423-7. PubMed ID: 2807180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarubicin in blastic crisis of chronic myelogenous leukemia.
    Lambertenghi-Deliliers G; Annaloro C; Cortellaro M; Pozzoli E; Oriani A; Polli EE
    Haematologica; 1991; 76(5):406-8. PubMed ID: 1806446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial.
    Schneller F; Schuler M; Schumacher K; Thaler J; Peschel C; Huber C; Aulitzky W
    Ann Hematol; 1998 Nov; 77(5):225-9. PubMed ID: 9858148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide, 6-thioguanine and idarubicin, an oral combination regimen (ETI) for the induction treatment of acute leukemia.
    Ruutu T; Elonen E
    Hematol Oncol; 1991; 9(2):87-92. PubMed ID: 1869245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
    Barone S; Baer MR; Sait SN; Lawrence D; Block AW; Wetzler M
    Am J Hematol; 2001 Jun; 67(2):119-24. PubMed ID: 11343384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
    Berman E; Raymond V; Gee T; Kempin SJ; Gulati S; Andreeff M; Kolitz J; Gabrilove J; Heller G; Young CW
    Semin Oncol; 1989 Feb; 16(1 Suppl 2):30-4. PubMed ID: 2928808
    [No Abstract]   [Full Text] [Related]  

  • 7. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia].
    Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
    Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Ravandi F; Giles F; Thomas D; Wierda W; Cortes J
    Leuk Lymphoma; 2007 Feb; 48(2):283-9. PubMed ID: 17325887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
    Koller CA; Kantarjian HM; Feldman EJ; O'Brien S; Rios MB; Estey E; Keating M
    Cancer; 1999 Dec; 86(11):2246-51. PubMed ID: 10590364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.
    Seiter K; Feldman EJ; Halicka HD; Traganos F; Darzynkiewicz Z; Lake D; Ahmed T
    J Clin Oncol; 1997 Jan; 15(1):44-51. PubMed ID: 8996123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Reversion to chronic phase of chronic myelogenous leukemia in blast crisis with small-dose daunorubicin and oral prednisolone].
    Kuyama J; Take H
    Rinsho Ketsueki; 1995 Dec; 36(12):1353-8. PubMed ID: 8587171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
    Tricot G; Weber G
    Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.
    Qing X; Qing A; Ji P; French SW; Mason H
    Exp Mol Pathol; 2018 Apr; 104(2):130-133. PubMed ID: 29501750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early phase II study of Idarubicin, a new anthracycline anticancer drug, in acute leukemia. Idarubicin Study Group].
    Ogawa M; Masaoka T; Yamada K; Kimura K
    Gan To Kagaku Ryoho; 1993 May; 20(7):897-906. PubMed ID: 8489296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
    Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.